These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 21785749

  • 1. Factors associated with long-term oral hypoglycemic agent responsiveness in korean patients with type 2 diabetes mellitus.
    Kim BY, Jung CH, Mok JO, Kim CH.
    Diabetes Metab J; 2011 Jun; 35(3):282-9. PubMed ID: 21785749
    [Abstract] [Full Text] [Related]

  • 2. Parameters measuring beta-cell function are only valuable in diabetic subjects with low body mass index, high blood glucose level, or long-standing diabetes.
    Lee SW, Lee S, Kim SH, Kim TH, Kang BS, Yoo SH, Lee MK, Koh WJ, Kang WS, Kim HJ.
    Yonsei Med J; 2011 Nov; 52(6):939-47. PubMed ID: 22028157
    [Abstract] [Full Text] [Related]

  • 3. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes].
    Machoy M.
    Ann Acad Med Stetin; 2004 Nov; 50(2):29-39. PubMed ID: 16529163
    [Abstract] [Full Text] [Related]

  • 4. Comparative evaluation of biphasic insulin with metformin and triple oral hypoglycemic agents (OHA) in type 2 diabetes patients.
    Alavudeen SS, Khobrani M, Dhanapal CK, Mir JI, Alshahrani SM, Khan NA, Alhossan A.
    Saudi Pharm J; 2020 Feb; 28(2):210-214. PubMed ID: 32042260
    [Abstract] [Full Text] [Related]

  • 5. Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy.
    Fujiwara D, Takahashi K, Suzuki T, Shii M, Nakashima Y, Takekawa S, Yoshida A, Matsuoka T.
    J Diabetes Investig; 2013 Nov 27; 4(6):618-25. PubMed ID: 24843717
    [Abstract] [Full Text] [Related]

  • 6. Changes of the glycemic control and therapeutic regimen for diabetes mellitus in the Japanese patients on hemodialysis.
    Sanai T, Tada H, Ono T, Fukumitsu T.
    Diabetes Metab Syndr; 2015 Nov 27; 9(4):244-6. PubMed ID: 25866098
    [Abstract] [Full Text] [Related]

  • 7. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S, Estacio RO, Jeffers B, Schrier RW.
    Proc Assoc Am Physicians; 1997 Mar 27; 109(2):181-9. PubMed ID: 9069587
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes.
    Gougeon R, Styhler K, Morais JA, Jones PJ, Marliss EB.
    Diabetes Care; 2000 Jan 27; 23(1):1-8. PubMed ID: 10857959
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.
    Rom J Intern Med; 2003 Jan 27; 41(2):153-62. PubMed ID: 15526500
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Association of insulin treatment versus oral hypoglycaemic agents with diabetic retinopathy and its severity in type 2 diabetes patients in Cameroon, sub-Saharan Africa.
    Jingi AM, Noubiap JJ, Essouma M, Bigna JJ, Nansseu JR, Ellong A, Mvogo CE.
    Ann Transl Med; 2016 Oct 27; 4(20):395. PubMed ID: 27867947
    [Abstract] [Full Text] [Related]

  • 16. Weight change after initiation of oral hypoglycemic monotherapy for diabetes predicts 5-year mortality: An observational study.
    Kocarnik BM, Moore KP, Smith NL, Boyko EJ.
    Diabetes Res Clin Pract; 2017 Jan 27; 123():181-191. PubMed ID: 28056429
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Jan 27; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 19. A reliable serum C-peptide index for the selection of an insulin regimen to achieve good glycemic control in obese patients with type 2 diabetes: an analysis from a short-term study with intensive insulin therapy.
    Suzuki T, Takahashi K, Fujiwara D, Shii M, Takekawa S, Matsuoka T.
    Diabetol Int; 2016 Sep 27; 7(3):235-243. PubMed ID: 30603269
    [Abstract] [Full Text] [Related]

  • 20. Effects of the treatment with acarbose in elderly overweight type 2 diabetic patients in poor glycemic control with oral hypoglycemic agents or insulin.
    Sangiorgio L, Attardo T, Condorelli L, Lunetta M.
    Arch Gerontol Geriatr; 2000 Aug 01; 31(1):27-34. PubMed ID: 10989161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.